2026 · 2nd Quarter (Apr 1 - June 30)

MCKESSON CORPATION AND ITS AFFILIATE US ONCOLOGY (FORMERLY US ONCOLOGY)

Filed by STANTON PARK GROUP.

Open official filing

Source-reported fields

Filing overview

Type: 2nd Quarter - Report
Posted: Jul 20, 2026
Income: $60,000.00
Expenses: Not reported
Registrant: STANTON PARK GROUP
Client: MCKESSON CORPATION AND ITS AFFILIATE US ONCOLOGY (FORMERLY US ONCOLOGY)
Filing UUID: 83c1d84e-ef17-4c5c-a8d0-9e7050d1e96c
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

MMM · Medicare/Medicaid

Medicare, oncology, radiation and imaging reimbursement issues; medicare physician payments; Oncology payment disparities in Medicare.; Health information technology; application of the sequester to cancer drug reimbursement; prompt pay discount; safety and security of the prescription drug supply chain; HR4299, Protecting Patient Access to Cancer and Complex Therapies Act.

Literal federal measure citations: HR4299

HCR · Health Issues

H.R.2484, Seniors Access to Critical Medications Act of 2025

Literal federal measure citations: H.R.2484

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.